# v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

> **NCT03447990** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 52 (actual)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction
- Dilated Cardiomyopathy

## Interventions

- **DRUG:** MYK-491
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03447990
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-06
- **Primary completion:** 2019-10-24
- **Final completion:** 2019-10-24
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2023-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03447990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03447990, "v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03447990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*